Life Sciences

The mission of HS Life Sciences is to provide a forum to review and discuss what is now possible in the industry.

Welcome to HS Life Sciences
Display Name
HS Life Sciences
Banner Image
Image

Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served as Synlogic’s president and chief executive officer since May 2018.

Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served as Synlogic’s president and chief executive officer since May 2018.

Translational Medicine in HSTalks’ The Biomedical & Life Sciences Collection

The Biomedical & Life Sciences Collection contains over 3,000 specially commissioned, seminar-style talks and interviews by leading world experts, including Nobel Laureates and Lasker prize winners. Topics range from basic science to therapeutic intervention, from single molecules to entire populations, relevant to drug discovery, pre-clinical research and development, clinical trials, medical and regulatory affairs and more. 

Dr. Garret FitzGerald is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he directs the Institute for Translational Medicine and Therapeutics.

Ronenn trained in internal medicine, epidemiology, and rheumatology at Johns Hopkins, and did postdoctoral training in inflammation and nutrition at Tufts University. He is currently Global Head of Translational Medicine Discovery and Profiling at Novartis Institutes for Biomedical Research (NIBR), based in Basel, Switzerland. He is also Adjunct Professor of Medicine and Nutrition at Tufts. He is an internationally recognized authority on sarcopenia, translational medicine, and the use of biomarkers in drug development.

Dr. Garret FitzGerald is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he directs the Institute for Translational Medicine and Therapeutics.

Ronenn trained in internal medicine, epidemiology, and rheumatology at Johns Hopkins, and did postdoctoral training in inflammation and nutrition at Tufts University. He is currently Global Head of Translational Medicine Discovery and Profiling at Novartis Institutes for Biomedical Research (NIBR), based in Basel, Switzerland. He is also Adjunct Professor of Medicine and Nutrition at Tufts. He is an internationally recognized authority on sarcopenia, translational medicine, and the use of biomarkers in drug development.

About the Henry Stewart Group

The Henry Stewart Group (HSG) has been a leader in providing graduate and continuing professional education in science, business and management for over 40 years through peer reviewed vocational journals, conferences and online education for commercial enterprises, business schools, medical schools, universities, non-profit and government.